Payment overview · 2025
General Payments
$683.08
36 reported records · 12 companies
Healthcare provider profile · identity verified
John Figel, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · STEUBENVILLE, OH · NPI 1336146448
Verified facts
What the public records show
CMS Open Payments records show John Figel, M.D. received $683.08 in general payments during 2025 across 36 reported records.
Novo Nordisk Inc accounted for 27.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 336 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $189.42 | 27.7% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $143.60 | 21.0% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $78.38 | 11.5% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $61.98 | 9.1% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $42.31 | 6.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.03 | 5.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.27 | 5.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.82 | 3.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.03 | 3.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.07 | 2.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.01 | 2.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.16 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $683.08 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $105.13 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $78.49 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $78.38 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $65.11 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $61.98 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $61.98 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $42.31 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.03 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.47 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.27 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.82 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 336 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 99 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
336 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 825 | 188 |
| Amlodipine Besylate | Amlodipine Besylate | 573 | 142 |
| Pantoprazole Sodium | Pantoprazole Sodium | 548 | 128 |
| Atorvastatin Calcium | Atorvastatin Calcium | 545 | 145 |
| Losartan Potassium | Losartan Potassium | 421 | 114 |
| Lisinopril | Lisinopril | 393 | 95 |
| Potassium Chloride | Potassium Chloride | 381 | 99 |
| Metoprolol Tartrate | Metoprolol Tartrate | 368 | 82 |
| Furosemide | Furosemide | 366 | 90 |
| Eliquis | Apixaban | 336 | 44 |
| Gabapentin | Gabapentin | 335 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 305 | 76 |
| Alprazolam | Alprazolam | 299 | 60 |
| Metformin Hcl | Metformin Hcl | 284 | 83 |
| Omeprazole | Omeprazole | 282 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 255 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 255 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 238 | 52 |
| Simvastatin | Simvastatin | 201 | 54 |
| Carvedilol | Carvedilol | 191 | 44 |
| Sertraline Hcl | Sertraline Hcl | 182 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 176 | 40 |
| Lorazepam | Lorazepam | 174 | 48 |
| Trazodone Hcl | Trazodone Hcl | 171 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 161 | 32 |
| Mirtazapine | Mirtazapine | 160 | 33 |
| Allopurinol | Allopurinol | 150 | 27 |
| Tramadol Hcl | Tramadol Hcl | 150 | 48 |
| Buspirone Hcl | Buspirone Hcl | 145 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 143 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 143 | 22 |
| Glimepiride | Glimepiride | 142 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 138 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 27 |
| Donepezil Hcl | Donepezil Hcl | 130 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 125 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 115 | 23 |
| Jardiance | Empagliflozin | 99 | 27 |
| Montelukast Sodium | Montelukast Sodium | 99 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 98 | 25 |
| Ozempic | Semaglutide | 93 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 92 | 26 |
| Prednisone | Prednisone | 92 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 21 |
| Meloxicam | Meloxicam | 91 | 33 |
| Cefuroxime | Cefuroxime Axetil | 89 | 70 |
| Spironolactone | Spironolactone | 86 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 37 |
| Memantine Hcl | Memantine Hcl | 81 | 20 |
| Atenolol | Atenolol | 80 | 22 |
| Januvia | Sitagliptin Phosphate | 80 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 69 | 15 |
| Azithromycin | Azithromycin | 66 | 58 |
| Tradjenta | Linagliptin | 64 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 17 |
| Midodrine Hcl | Midodrine Hcl | 61 | 17 |
| Risperidone | Risperidone | 61 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 60 | 11 |
| Ezetimibe | Ezetimibe | 60 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 59 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 58 | 15 |
| Propranolol Hcl | Propranolol Hcl | 58 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 23 |
| Warfarin Sodium | Warfarin Sodium | 56 | 13 |
| Farxiga | Dapagliflozin Propanediol | 54 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | 18 |
| Levetiracetam | Levetiracetam | 52 | suppressed |
| Latanoprost | Latanoprost | 50 | suppressed |
| Sucralfate | Sucralfate | 50 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 46 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | suppressed |
| Procrit | Epoetin Alfa | 44 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | suppressed |
| Famotidine | Famotidine | 41 | 22 |
| Glipizide | Glipizide | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 31 |
| Lovastatin | Lovastatin | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 37 | suppressed |
| Clonazepam | Clonazepam | 37 | 11 |
| Temazepam | Temazepam | 37 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Rivastigmine | Rivastigmine | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | 13 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 22 |
| Methylprednisolone | Methylprednisolone | 27 | 23 |
| Baclofen | Baclofen | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 24 | suppressed |
| Rexulti | Brexpiprazole | 24 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 24 | 11 |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 19 |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Niacin Er | Niacin | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 15 |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $683.08 · 36 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, Wegovy | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error